Home > Dermatology > AAD 2022 > What’s Hot in Rare Diseases > Add-on apremilast may improve recalcitrant dermatomyositis

Add-on apremilast may improve recalcitrant dermatomyositis

Presented By
Prof. Carole Bitar, Tulane University School of Medicine, USA
Presented by
Carole Bitar
Conference
AAD 2022
Trial
Phase 2
With an overall response rate of 87.5%, apremilast demonstrated efficacy as an add-on treatment for recalcitrant dermatomyositis without raising safety concerns in a small phase 2a trial. An additional transcriptome analysis revealed a downregulation of key signalling pathways by apremilast. Dermatomyositis is 1 of the 3 main types of idiopathic inflammatory myopathies. Most patients present with typical skin signs and half of them also suffer from muscle weakness [1,2]. There is a demand for more efficacious treatment options because even with extensive use of current therapies, a great proportion of patients is not adequately controlled [3]. A phase 2a open-label trial (NCT03529955) investigated the phosphodiesterase-4 inhibitor apremilast as an add-on therapy for recalcitrant cutaneous dermatomyositis [4]. The study included 8 patients who met the inclusi...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on